[go: up one dir, main page]

PE20070767A1 - Composicion farmaceutica fotoestable que contiene brivudina - Google Patents

Composicion farmaceutica fotoestable que contiene brivudina

Info

Publication number
PE20070767A1
PE20070767A1 PE2006001181A PE2006001181A PE20070767A1 PE 20070767 A1 PE20070767 A1 PE 20070767A1 PE 2006001181 A PE2006001181 A PE 2006001181A PE 2006001181 A PE2006001181 A PE 2006001181A PE 20070767 A1 PE20070767 A1 PE 20070767A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition containing
amount
hsv
containing brivudine
Prior art date
Application number
PE2006001181A
Other languages
English (en)
Inventor
Marc Wihsmann
Reinhard Schmitz
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of PE20070767A1 publication Critical patent/PE20070767A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) BRIVUDINA EN UNA CANTIDAD DESDE 0,05-2% p/p; B) UN AGENTE FORMADOR SELECCIONADO ENTRE POLIVINILPIRROLIDONA (PVP), ALCOHOL POLIVINILICO (PVA) Y POLIACRILATO EN UNA CANTIDAD ENTRE 0,5-10% p/p. CONTIENE ADEMAS UN CONSERVANTE Y UN ANTIOXIDANTE. LA COMPOSICION ES DE PREFERENCIA OFTALMICA AL QUE SE LE ADICIONA UNA DROGA ANTIINFLAMATORIA NO ESTEROIDE FULBIPROFENO UTILES EN EL TRATAMIENTO DE LA QUERATITIS EPITELIAL POR HSV, QUERATITIS ESTROMAL POR HSV, COMPLICACIONES OCULARES DEL HERPES ZOSTER OFTALMICO
PE2006001181A 2005-09-29 2006-09-28 Composicion farmaceutica fotoestable que contiene brivudina PE20070767A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005046769A DE102005046769A1 (de) 2005-09-29 2005-09-29 Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)

Publications (1)

Publication Number Publication Date
PE20070767A1 true PE20070767A1 (es) 2007-08-13

Family

ID=37561306

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001181A PE20070767A1 (es) 2005-09-29 2006-09-28 Composicion farmaceutica fotoestable que contiene brivudina

Country Status (33)

Country Link
US (1) US20080249061A1 (es)
EP (1) EP1940353B1 (es)
JP (1) JP2009509993A (es)
KR (1) KR20080053319A (es)
CN (1) CN101272765A (es)
AP (1) AP2008004394A0 (es)
AR (1) AR056551A1 (es)
AT (1) ATE489076T1 (es)
AU (1) AU2006299115A1 (es)
BR (1) BRPI0616449A2 (es)
CA (1) CA2624111A1 (es)
CR (1) CR9839A (es)
CY (1) CY1111059T1 (es)
DE (2) DE102005046769A1 (es)
DK (1) DK1940353T3 (es)
EA (1) EA012975B1 (es)
EC (1) ECSP088310A (es)
ES (1) ES2356774T3 (es)
HN (1) HN2008000497A (es)
HR (1) HRP20110085T1 (es)
IL (1) IL190466A0 (es)
MA (1) MA29887B1 (es)
NO (1) NO20081488L (es)
PE (1) PE20070767A1 (es)
PL (1) PL1940353T3 (es)
PT (1) PT1940353E (es)
RS (1) RS51615B (es)
SI (1) SI1940353T1 (es)
TN (1) TNSN08094A1 (es)
TW (1) TW200744664A (es)
UA (1) UA90911C2 (es)
WO (1) WO2007039201A2 (es)
ZA (1) ZA200802729B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006130A2 (en) * 2007-06-28 2009-01-08 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
US20090196833A1 (en) * 2008-02-06 2009-08-06 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
PT2898888T (pt) 2014-01-22 2019-07-16 Visufarma B V Composição que compreende iota-carragenina contra conjuntivite viral
AU2017261303B9 (en) * 2016-05-06 2021-09-23 Sacsh, Inc. Ophthalmic compositions
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY136633A (en) * 2001-01-17 2008-11-28 Berlin Chemie Ag Stabilized brivudine topical formulations
DE10162593A1 (de) * 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen

Also Published As

Publication number Publication date
WO2007039201A2 (en) 2007-04-12
EA012975B1 (ru) 2010-02-26
ZA200802729B (en) 2009-09-30
SI1940353T1 (sl) 2011-03-31
ECSP088310A (es) 2008-05-30
EP1940353B1 (en) 2010-11-24
KR20080053319A (ko) 2008-06-12
MA29887B1 (fr) 2008-10-03
CA2624111A1 (en) 2007-04-12
CR9839A (es) 2008-10-31
AU2006299115A1 (en) 2007-04-12
AR056551A1 (es) 2007-10-10
CN101272765A (zh) 2008-09-24
PL1940353T3 (pl) 2011-05-31
JP2009509993A (ja) 2009-03-12
BRPI0616449A2 (pt) 2011-06-21
ATE489076T1 (de) 2010-12-15
ES2356774T3 (es) 2011-04-13
IL190466A0 (en) 2008-11-03
UA90911C2 (ru) 2010-06-10
PT1940353E (pt) 2011-02-25
TW200744664A (en) 2007-12-16
TNSN08094A1 (en) 2009-07-14
DK1940353T3 (da) 2011-01-24
EA200800646A1 (ru) 2008-10-30
DE102005046769A1 (de) 2007-04-05
HRP20110085T1 (hr) 2011-03-31
AU2006299115A2 (en) 2008-05-29
US20080249061A1 (en) 2008-10-09
HN2008000497A (es) 2010-09-10
EP1940353A2 (en) 2008-07-09
RS51615B (en) 2011-08-31
CY1111059T1 (el) 2015-06-11
DE602006018505D1 (de) 2011-01-05
WO2007039201A3 (en) 2007-10-04
AP2008004394A0 (en) 2008-04-30
NO20081488L (no) 2008-03-26

Similar Documents

Publication Publication Date Title
PE20070767A1 (es) Composicion farmaceutica fotoestable que contiene brivudina
AR078161A1 (es) Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PE20080053A1 (es) Composiciones oftalmicas de alcaftadina
PE20130183A1 (es) Fosforamidatos de nucleosido
AR060922A1 (es) Producto absorbente
ECSP088239A (es) Composición de liberación de fármaco sostenida
CL2020002252A1 (es) Formulación oftálmica.
ES2523660T3 (es) Composición para un material de electrodo, utilización de la misma y procedimiento para producir una célula solar
PE20110162A1 (es) Yoduro de povidona, un nuevo conservante alternativo para composiciones oftalmicas
AR037448A1 (es) Composiciones para el tratamiento de semillas
PE20011122A1 (es) DERIVADOS DE PURINA-2-ILCARBOXAMIDA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA
CL2008002228A1 (es) Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas.
JP2012031075A (ja) イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物
CO5280222A1 (es) Composicion farmaceutica que comprende pemetrexed
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
CL2011001764A1 (es) Composicion farmaceutica que comprende (2r,3r,4r,5r)-5-(4-amino-2-oxo-2h-pirimidin-1-il)-4-fluoro-2-isobutiriloximetil-4-metil-tetrahidro-furan-3-il ester de acido isobutirico e hidroxipropilcelulosa; y uso en el tratamiento de una enfermedad mediada por el virus de la hepatitis c.
JPWO2015041193A1 (ja) 両性イオン性ソフトコンタクトレンズ用眼科用組成物
UY27596A1 (es) Formulación oral de fludara purísimo con liberación rátida del ingrediente
AR073781A1 (es) Composicion farmaceutica para el tratamiento del glaucoma, hipertension ocular o retinitis pigmentosa.
JP1748473S (ja) プレス機のジョー
UY28152A1 (es) (4-(3-aminometilfenil)piperidin-1-il)-(5-(2-fluorofeniletinil)furan-2-il)-metanona como inhibidor de triptasa de mastocitos.
TH88745A (th) สารผสมเภสัชกรรมที่มีคงสภาพต่อแสงที่มีไบรวูดีน สำหรับการรักษาเฮอร์ปีติคคีราติติส
AR043793A1 (es) Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana
AR046043A1 (es) Asociacion de un agente anti-aterotrombotico y un agente anti-agregacion de plaquetas y composiciones farmaceuticas que los contienen
AR024032A1 (es) Un metodo para controlar la infeccion por sphaerotheca pannosa en rosales mediante el uso de esteres de cera.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed